The tissue procurement and analysis core facility serves an integral function of not only providing tissue procurement, processing and disbursement of tissue to SPORE investigators but also provides an important analysis component. The core is expanding this analysis component to the population based studies of the SPORE to allow for cost effective centralization of resources coupled with expert maintenance of quality control and quality assurance practices. The procurement section efficiently accesses all breast surgical procedures and obtains blood samples and when available fresh tissue on all patients giving informed consent. The tissues are entered in a database and distributed to the SPORE investigators as processed DNA, RNA or tissue sections as requested. A bark of peripheral blood lymphocytes is also maintained on all breast patients. The tissue analysis section provides immunohistochemical and other protein analysis for the SPORE. A major focus of this section provides analyses for the novel genes which have been discovered via the basic science projects, assessing the levels of expression of these genes in normal and malignant breast tissues. This section is being expanded to also include the population based studies of the SPORE (Project#2: Carolina Breast Cancer Study, Project#3: DCIS Study, Project#5: Mayo Benign Breast Disease Study) for the expression of tumor suppressor genes, oncogenes and proliferation markers. Expression of the protein products of these genes will be related to the molecular analyses as well as to exposure information obtained.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058223-08S1
Application #
6356234
Study Section
Project Start
1999-08-05
Project End
2001-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2000
Total Cost
$168,504
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820

Showing the most recent 10 out of 598 publications